A three-year randomised controlled clinical trial demonstrated that DGF could effectively improve glucolipid metabolism, reduce insulin dosage in patients with diabetes, lower the ultrasound score of lower-extremity atherosclerosis, improve left ventricular diastolic function, and reduce the risk of new-onset coronary heart disease and all-cause mortality (Heng et al., 2019). This evidence concerns the gene INS and diabetes mellitus.